I am a Cancer Research UK clinician scientist and honorary medical oncology consultant with 15 years research experience in drug and biomarker development for castration resistant prostate cancer (CRPC). I am internationally recognised, having published extensively, been widely cited and presented and chaired sessions at major international meetings. I sit on several scientific advisory boards and grant review committees and review manuscripts for the major journals. I lead the Treatment Resistance group in the University College London (UCL) Cancer Institute focusing on functional and genomic studies of mechanisms of resistance in prostate cancer and the development of circulating biomarker based strategies for patient molecular characterisation and stratification. My clinical practice based in the University College London Hospital (UCLH) manages men with CRPC, the majority of whom are treated in the setting of clinical trials. I have led as chief investigator several multi-centre national and international clinical trials in CRPC. I lead the PCF-SELECT consortium to clinically implement a plasma-based test in the management of prostate cancer, the STRATOSPHere consortium to develop rational treatments for molecularly stratified prostate cancer starting long-term hormone therapy and the abiraterone-enzalutamide comparison in the STAMPEDE trial. I provide mentorship for medical oncology fellows and trainees and laboratory-based PhD students and post-doctoral fellows.